Queen Mary University of London spin-out Activiomics enters into research programme with Kyowa Hakko Kirin.

Life sciences firm Activiomics has built on its contract research agreement with Japan-based pharmaceutical firm Kyowa Hakko Kirin (KHK) by entering into a new research programme.

The London-based Queen Mary University of London spin-out will apply its cell signalling TIQUAS platform to lead compounds supplied by KHK.

Activiomics has received $805k in venture funding. The financing came from a 2011 venture round, backed solely by commercialisation firm the IP Group.

Hiroshi Okazaki, managing officer at Kyowa Hakko Kirin, said: “We have been impressed with the results from the initial stages of our partnership with Activiomics and look forward to working with them on this new programme.”

Kevin FitzGerald, chief executive of Activiomics, added: “We are delighted to have signed a new contract with Kyowa Hakko Kirin which follows on from a previous successful study. The extension of the partnership is a strong endorsement of the quality and quantity of information that can be generated using our technology platform.”